Lilly led the S&P 500 as money fled AI stocks for healthcare. At 31x forward earnings, the defensive bid is cheaper than Lilly usually trades

DuChembio jumps on South Korea approval hopes for Lilly Alzheimers drug

Eli Lilly and Company (LLY) ha subido un 3,9% hoy. Aquí hay un análisis sobre lo que podría haber causado esta p.

Eli Lilly and Company stocks have been trading up by 3.96 percent on optimism over its breakthrough obesity drug developments. Key Takeaways LLY Traders Need To Know Phase 3 data for oral GLP-1 Foundayo show non-inferior cardiovascular safety versus insulin glargine, with better A1C, weight loss,

Eli Lilly and Company stocks have been trading up by 4.0 percent following strong demand signals for its obesity drugs. Key Takeaways For Active Traders Oral GLP‑1 drug Foundayo matched insulin glargine on major heart events in high‑risk type 2 diabetes while delivering better blood sugar control, weight loss, kidney protection, and lower mortality signals.…

Los ingresos alcanzaron los 22,97 mil millones de dólares en el segundo trimestre. Las acciones de Eli Lilly cuestan 1.054,60 euros en octubre

Eli Lilly has outlined its strategy to lead the next-generation obesity drug market with its triple agonist Retatrutide, building on the success of…

Eli Lilly (LLY) just put fresh clinical data on the table, showing that combining Taltz and Zepbound shifted more psoriasis and metabolic biomarkers than Taltz alone for patients with psoriasis and obesity. Eli Lilly shares trade at US$1,166.51 after a small 1 day decline of 1.36%, while a 30 day share price return of 4.55% and a year to date gain of 7.97% point to steady, if moderating, momentum ahead of upcoming earnings and heavy news flow on obesity, cardiometabolic and immunology...

Eli Lilly stock is at EUR 1042.80 pre-market at Lang & Schwarz on October 14, 2026, down 0.46 percen

Bristol Myers Squibb recovered to $7.1B in net income while Eli Lilly more than doubled profits to $20.6B, a stark contrast in momentum that reshapes the value-versus-growth debate.

Eli Lilly recently reported exploratory Phase 3b data from the TOGETHER-PsO trial showing that combining Taltz with Zepbound in adults with moderate-to-severe plaque psoriasis and obesity or overweight altered far more immune and metabolic biomarkers than Taltz alone, with broader responses emerging as early as Week 12. The findings highlight a potential immunometabolic link between psoriasis and obesity, suggesting Lilly could unlock new treatment approaches by pairing its immunology and...

Eli Lilly (LLY) reached $1 at the closing of the latest trading day, reflecting a -1.04% change compared to its last close.